Psilocybin

Primary targets and binding profile: Psilocybin is pharmacologically inert until conversion to psilocin. Psilocin is a serotonergic psychedelic whose acute subjective effects depend strongly on 5-HT2A receptor agonism; human and translational studies further implicate 5-HT2C and 5-HT1A signalling in shaping acute effects and downstream physiological responses. In receptor binding work, psilocin shows broadly similar submicromolar affinities across 5-HT2A, 5-HT2C, and 5-HT1A (for example, reported Ki ranges around 120–173 nM for 5-HT2A; 79–311 nM for 5-HT2C; and ~146–152 nM for 5-HT1A), supporting a multi-receptor serotonergic profile rather than an exclusively 5-HT2A-selective mechanism.

Metabolism and active metabolites: In humans, psilocybin is rapidly dephosphorylated to psilocin via alkaline phosphatase and related phosphatases/esterases; psilocin is then cleared mainly through glucuronidation (psilocin-O-glucuronide is a major circulating and urinary metabolite) with additional oxidative pathways (including monoamine oxidase-mediated routes leading to metabolites such as 4-hydroxyindole-3-acetic acid). Contemporary pharmacokinetic reviews highlight that plasma concentrations of conjugated psilocin can exceed unconjugated psilocin, and that elimination is largely complete within a day despite wide inter-individual variability in exposure.

Onset, peak, duration, and routes: In supervised clinical use, psilocybin is typically administered orally (capsule or similar), with onset commonly within ~20–40 minutes, peak subjective effects at ~60–90 minutes, and an active duration around 4–6 hours; some clinical programmes describe dosing-day psychedelic effects lasting roughly 6–8 hours when psychological support and recovery time are included. Intravenous administration produces a faster peak and can shorten the experiential window relative to oral dosing by bypassing absorption and first-pass metabolism; however, IV psilocybin remains primarily a research route rather than a standard therapeutic format.

Dose–response characteristics in trials: Modern depression trials have converged on fixed-dose regimens broadly comparable to 25 mg oral psilocybin (or equivalent), with evidence of dose separation in TRD development programmes. In the COMPASS Phase IIb dose-finding trial, participants were randomised to 1 mg, 10 mg, or 25 mg; the 25 mg condition showed the clearest symptomatic improvement versus 1 mg at early follow-up. The Phase III TRD programme focused on 25 mg dosing (single dose versus placebo in COMP005; and one or two 25 mg doses versus a 1 mg control in COMP006), reflecting a strategic shift towards effect confirmation and durability optimisation.

Neuroimaging and biomarkers: Mechanistic studies suggest that psilocybin can acutely and subacutely alter large-scale brain network dynamics. In an early fMRI study in TRD, Carhart-Harris and colleagues reported post-treatment decreases in cerebral blood flow in temporal regions including the amygdala (correlating with symptom improvement) alongside changes in default mode network connectivity. PET data indicate that intensity of the acute psychedelic experience correlates with 5-HT2A receptor occupancy and plasma psilocin exposure, linking central target engagement to phenomenology rather than assuming it.

Neuroplasticity mechanisms remain a central hypothesis but are still being translated from preclinical to clinical evidence. In rodents, a single dose has been shown to induce rapid increases in dendritic spine density and size in frontal cortex (on the order of ~10%), with persistence for weeks, supporting a plausible biological substrate for enduring behavioural change after brief exposure. In humans, peripheral biomarkers such as BDNF are under active investigation, but recent syntheses caution that peripheral BDNF changes are inconsistent across studies and may not reliably index brain plasticity in a clinically actionable way.

Discovery, isolation, and early medical use: Western medical and scientific interest in psilocybin intensified in the mid-20th century following ethnomycological documentation of ritual mushroom use. Albert Hofmann at Sandoz isolated psilocybin from Psilocybe mexicana in 1958 and reported synthesis shortly thereafter; Sandoz marketed psilocybin as Indocybin for research and psychiatric investigation in an era when “psychotomimetic” and psychotherapy-adjunct paradigms were being explored across several compounds.

Scheduling and the research hiatus: The late 1960s and early 1970s brought pronounced restriction. In the US, the Controlled Substances Act formalised Schedule I controls that sharply constrained clinical access, while the 1971 UN Convention on Psychotropic Substances established an international control framework that many jurisdictions implemented via national prohibition and restrictive research licensing. This created a multi-decade trough in clinical psychedelic research capacity, with sporadic exceptions.

Modern revival and methodological maturation: A key institutional catalyst was the formation of the Heffter Research Institute (incorporated in 1993), which helped fund and coordinate credible human work during a period when public funding and institutional willingness were limited. In Europe, Franz Vollenweider’s late-1990s human psychopharmacology studies in Zürich contributed to a modern neurobiological framing of classic psychedelic effects, including receptor-specific blockade paradigms that strengthened causal inference about serotonergic mechanisms. Over the 2000s–2010s, methodological sophistication increased: greater attention to screening and safety monitoring, use of active placebos to partially mitigate expectancy, incorporation of validated outcome measures, and integration of neuroimaging and receptor-occupancy approaches.

From “renaissance” to product development: The 2010s–2020s saw psilocybin move from academic proof-of-concept into structured clinical development in depression, oncology-related distress, and addiction, culminating in large multisite trials and now replicated Phase III signals in TRD. The field’s centre of gravity has shifted towards standardisation (dose, setting, therapist training, and outcome measurement), regulatory engagement, and health-system integration questions—an evolution captured by the emergence of compassionate-use frameworks (for example in Germany) and by industry attempts to reduce practical barriers through new formulations and analogues.

Common adverse events in clinical trials: Across monitored studies, therapeutic-dose psilocybin is most consistently associated with transient headache, nausea, fatigue, dizziness, and acute anxiety, alongside short-lived increases in blood pressure; systematic reviews and meta-analyses conclude that these effects are usually self-limiting and resolve within 48 hours under clinical supervision, but emphasise that more rigorous and standardised adverse-event measurement is needed as trials scale and broaden eligibility.

Serious adverse events and psychiatric vulnerability: Serious adverse events (SAEs) are uncommon overall in contemporary psychedelic trials, but they do occur, and appear concentrated in participants with pre-existing neuropsychiatric disorders rather than healthy volunteer samples. Suicidal ideation and intentional self-injury have been reported in TRD populations across dose groups in psilocybin trials, requiring careful interpretation because baseline risk is high in TRD cohorts; nonetheless, these events materially shape risk management and regulatory scrutiny. COMPASS Pathways’ Phase III press release stated that no serious unexpected suspected adverse reactions occurred, while still reporting adverse events such as headache and nausea as common, and highlighting ongoing monitoring of suicidality and related events.

Cardiovascular and other organ-system considerations: Psilocybin does not appear to carry a prominent direct organ-toxicity signal in controlled single- or few-dose studies, but transient autonomic effects (blood pressure and heart rate increases) are sufficiently consistent that protocols usually exclude uncontrolled hypertension and significant cardiovascular instability and require vital-sign monitoring during dosing and recovery. Contemporary adverse-event reviews note that medical intervention is rarely needed, but can be required in isolated cases (for example for sustained anxiety, hypertension, or emergent psychiatric distress), reinforcing the clinical importance of skilled session monitoring rather than assuming benignity.

Abuse potential and dependence liability: Psilocybin’s dependence liability is generally considered low relative to reinforcing substances such as opioids, stimulants, or alcohol, with rapid tolerance and minimal evidence of a classic withdrawal syndrome. A structured “8-factor” analysis aligned to the US Controlled Substances Act has argued that medically administered psilocybin would likely warrant rescheduling if approved, but that appropriate controls would still be needed due to acute impairment, diversion risk, and the need for supervised administration.

Contraindications and drug–drug interactions: Most modern protocols exclude patients with current psychotic disorders and typically screen out bipolar I disorder or strong bipolar-spectrum risk because case-report syntheses suggest potential for mania activation in vulnerable individuals. Concomitant medication management remains an evolving area: many trials historically required tapering serotonergic antidepressants to minimise confounding and potential blunting of psilocybin effects, but scoping reviews suggest that classic psychedelics combined with conventional antidepressants are often tolerated without robust evidence of serotonin syndrome, while acknowledging that available evidence is limited and heterogeneous. In contrast, coadministration with lithium is a clearly elevated risk scenario: analyses of naturalistic reports have associated lithium-plus-psychedelic use with a substantial seizure signal, and this risk is taken seriously in contemporary clinical screening.

Risk management safeguards and likely post-approval controls: Contemporary psilocybin protocols operationalise safety through structured “set and setting” safeguards—screening, preparation sessions, continuous monitoring during dosing, and integration support afterwards—because important harms are psychological and behavioural rather than toxicological. If a regulated psilocybin medicine receives marketing authorisation in the US, a restricted distribution and supervised-administration model analogous in spirit (though not identical in content) to existing REMS programmes for psychoactive in-clinic treatments is plausible, given established FDA precedent for medicines requiring on-site dosing and post-dose monitoring for dissociation/sedation (as with esketamine).

Indications with the strongest evidence: TRD now sits at the top of the evidence hierarchy because it has replicated Phase III trial success in a consistent dosing framework (25 mg COMP360 with psychological support) and a clearly defined regulatory path. If subsequent full datasets confirm clinically meaningful durability and acceptable safety in a high-risk population, TRD is positioned to become the first mainstream medical indication for a psilocybin-based intervention in major jurisdictions.

MDD is the next-most mature indication: multiple Phase II datasets (including multisite randomised evidence with 25 mg dosing versus active placebo) support efficacy and tolerability in selected patients, and Phase III programmes are active (notably Usona’s uAspire). The key near-term clinical questions are not simply symptom reduction but durability, relapse prevention, and how psilocybin-assisted interventions compare against best-available pharmacotherapy and psychotherapy in broader, more comorbid real-world populations.

Oncology-related distress remains compelling but methodologically complex: the effect sizes in the 2016 RCTs were large, and the conceptual fit with palliative psychiatry is strong, but earlier crossover designs and the difficulty of long-term blinding make it challenging to specify optimal dosing frequency, patient selection, and service structure. Larger pragmatic trials and real-world compassionate-use data (where permitted) are likely to clarify clinical value and boundaries of indication.

Addiction profiles represent a high-opportunity, high-complexity frontier. Alcohol use disorder has the most robust randomised evidence so far, with meaningful reductions in heavy drinking metrics over many months; tobacco cessation signals remain unusually strong for a brief intervention, but require confirmatory trials with rigorous comparators and scalable delivery models. Opioid, stimulant, and behavioural addictions are increasingly targeted, but development is constrained by comorbidity, safety screening, and the need to integrate pharmacotherapy with structured behaviour-change protocols.

What next-generation trials are likely to test: Several design tensions are now central. First, medication management: evidence is emerging on whether patients must discontinue SSRIs/SNRIs, with scoping reviews suggesting tolerability but potential blunting, and dedicated trials explicitly studying SSRI interactions. Second, dosing frequency: Phase III TRD programmes are already testing one versus two sessions to optimise durability, and real-world compassionate use may generate further insights while remaining tightly limited. Third, personalisation: baseline neuroimaging/connectivity and other predictors are being evaluated to identify who benefits most and who may be harmed, which is essential for both clinical safety and payer acceptability.